Inventor · disambiguated record
Olaf Kinstler
Also filed as: KINSTLER OLAF · KINSTLER OLAF B · KINSTLER OLAF BORIS
19 granted patents·7 pending applications·2,334 citations·filing 1994–2013
97Inventor score
Top patents by PatentIndex Score
26 records- 0198US5824784AN-terminally chemically modified protein compositions and methodsAMGEN INC·Filed 1994·Granted Oct 20, 1998·779 cites·12 claims
- 0297US7662933B2N-terminally chemically modified protein compositions and methodsAMGEN INC·Filed 2006·Granted Feb 16, 2010·59 cites·15 claims
- 0397US6586398B1Chemically modified novel erythropoietin stimulating protein compositions and methodsAMGEN INC·Filed 2000·Granted Jul 1, 2003·396 cites·5 claims
- 0497US6420339B1Site-directed dual pegylation of proteins for improved bioactivity and biocompatibilityAMGEN INC·Filed 1998·Granted Jul 16, 2002·288 cites·4 claims
- 0597US5985265AN-terminally chemically modified protein compositions and methodsAMGEN INC·Filed 1997·Granted Nov 16, 1999·229 cites·6 claims
- 0693US8143380B2Therapeutic peptidesWALKER KENNETH W·Filed 2005·Granted Mar 27, 2012·14 cites·11 claims
- 0793US5795569AMono-pegylated proteins that stimulate megakaryocyte growth and differentiationAMGEN INC·Filed 1994·Granted Aug 18, 1998·137 cites·11 claims
- 0893US5766581AMethod for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiationAMGEN INC·Filed 1995·Granted Jun 16, 1998·141 cites·6 claims
- 0989US7160924B2Protein conjugates with a water-soluble biocompatible, biodegradable polymerAMGEN INC·Filed 2003·Granted Jan 9, 2007·42 cites·7 claims
- 1088US6956027B2N-terminally chemically modified protein compositions and methodsAMGEN INC·Filed 2002·Granted Oct 18, 2005·18 cites·28 claims
- 1186US5770577ABDNF and NT-3 polypeptides selectively linked to polyethylene glycolAMGEN INC·Filed 1994·Granted Jun 23, 1998·69 cites·16 claims
- 1282US5574018AConjugates of vitamin B12 and proteinsAMGEN INC·Filed 1994·Granted Nov 12, 1996·77 cites·24 claims
- 1380US8258262B2N-terminally chemically modified protein compositions and methodsKINSTLER OLAF B·Filed 2009·Granted Sep 4, 2012·4 cites·14 claims
- 1479US7262166B2Chemically modified novel erythropoietin stimulating protein compositions and methodsAMGEN INC·Filed 2003·Granted Aug 28, 2007·10 cites·16 claims
- 1578US5900404AChemical modification of proteins to improve biocompatibility and bioactivityAMGEN INC·Filed 1997·Granted May 4, 1999·30 cites·3 claims
- 1675US6017876AChemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivityAMGEN INC·Filed 1998·Granted Jan 25, 2000·24 cites·3 claims
- 1773US6770746B2Chemical modification of proteins to improve biocompatibility and bioactivityAMGEN INC·Filed 2002·Granted Aug 3, 2004·4 cites·3 claims
- 1868US6420340B2Chemical modification of proteins to improve biocompatibility and bioactivityAMGEN INC·Filed 2000·Granted Jul 16, 2002·2 cites·6 claims
- 1968US2008206184A1Chemically Modified Protein Compositions and MethodsAMGEN INC·Filed 2008·Application pending·0 cites
- 2061US6204247B1Chemical modification of proteins to improve biocompatibility and bioactivityAMGEN INC·Filed 1999·Granted Mar 20, 2001·11 cites·5 claims
- 2159US2005215710A1Chemically modified protein compositions and methodsGEGG COLIN V JR·Filed 2005·Application pending·0 cites
- 2257US2013189219A1N-terminally chemically modified protein compositions and methodsKINSTLER OLAF B·Filed 2013·Application pending·0 cites
- 2356US2012296072A1N-terminally chemically modified protein compositions and methodsKINSTLER OLAF B·Filed 2012·Application pending·0 cites
- 2456US2006264377A1Chemically modified novel erythropoietin stimulating protein compositions and methodsAMGEN INC·Filed 2006·Application pending·0 cites
- 2555US2003053982A1N-terminally chemically modified protein compositions and methodsFiled 2002·Application pending·0 cites
- 2637US2005124537A1Modulators of receptors for parathyroid hormone and parathyroid hormone-related proteinAMGEN INC·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →